Milano Gérard
Laboratoire d'oncopharmacologie, EA3836, Centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice Cedex 2.
Bull Cancer. 2008 Oct;95(10):1003-5. doi: 10.1684/bdc.2008.0735.
The majority of current major advances in the management of main human malignancies including breast, colorectum and head and neck result from the introduction of targeted therapies. An optimal application of targeted therapy needs a knowledge for the tumoral status of the target itself. It is also interesting to dispose of biological informations resulting from the interactions between treatment and target (biological proof of the concept). These informations are at the basis of the conception of new clinical protocols in oncology. In this context the role of molecular biology units is determinant. Examples of concrete applications of this strategy will be detailled particularly for the MINDACT Trial in breast cancer and for the KRAS status in the setting of EGFR targeting therapies in advanced colorectal cancer.
目前，包括乳腺癌、结直肠癌和头颈癌在内的主要人类恶性肿瘤治疗方面的大多数重大进展都源于靶向治疗的引入。靶向治疗的最佳应用需要了解靶点自身的肿瘤状态。掌握治疗与靶点相互作用产生的生物学信息（概念的生物学证据）也很有意义。这些信息是肿瘤学新临床方案设计的基础。在这种背景下，分子生物学部门的作用至关重要。将特别详细介绍该策略的具体应用实例，尤其是乳腺癌的MINDACT试验以及晚期结直肠癌中表皮生长因子受体（EGFR）靶向治疗背景下的KRAS状态。
